Literature DB >> 16322687

p16(Ink4a) inhibits histologic progression and angiogenic signaling in min colon tumors.

Steven L Gibson1, Amelie Boquoi, Tina Chen, Norman E Sharpless, Colleen Brensinger, Greg H Enders.   

Abstract

The Ink4a/Arf tumor suppressor locus is widely inactivated in cancer but little is known about the tumor biology of its two products, p16(Ink4a) (p16) and Arf. Both the p16 and Arf promoters are methylated in a significant fraction of human colon carcinomas, implying a functional role. We have demonstrated previously that Ink4a/Arf-null colon tumors display increased growth and vascularity in C57Bl6 mice carrying the Min (multiple intestinal neoplasia) mutation. We present here an analysis in a mixed genetic background of Min colon tumors (N=215) in mice with or without selective deficiencies in p16 or Arf, respectively. Absence of Arf did not significantly alter tumor formation. In contrast, tumors in mice lacking p16 were moderately larger and redder. Histological analysis demonstrated that these tumors contained significantly more pockets of necrosis (p=0.02), a marker of carcinoma in situ; less apoptosis (p=0.02); and higher red blood cell density (p=0.02, 0.006 within vessels). Biochemical analyses demonstrated increased levels of vascular endothelial cell growth factor (VEGF, p<0.01). Exogenous p16 expression in human colon tumor cells in vitro inhibited VEGF production. These results suggest that p16 constrains colon tumor progression, in part through inhibiting angiogenic signaling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16322687      PMCID: PMC1924686          DOI: 10.4161/cbt.4.12.2303

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  38 in total

1.  The cell cycle inhibitor p16(INK4A) sensitizes lymphoblastic leukemia cells to apoptosis by physiologic glucocorticoid levels.

Authors:  M J Ausserlechner; P Obexer; G J Wiegers; B L Hartmann; S Geley; R Kofler
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

2.  Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer.

Authors:  N Burri; P Shaw; H Bouzourene; I Sordat; B Sordat; M Gillet; D Schorderet; F T Bosman; P Chaubert
Journal:  Lab Invest       Date:  2001-02       Impact factor: 5.662

3.  p16(INK4a) expression begins early in human colon neoplasia and correlates inversely with markers of cell proliferation.

Authors:  C Y Dai; E E Furth; R Mick; J Koh; T Takayama; Y Niitsu; G H Enders
Journal:  Gastroenterology       Date:  2000-10       Impact factor: 22.682

4.  Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis.

Authors:  N E Sharpless; N Bardeesy; K H Lee; D Carrasco; D H Castrillon; A J Aguirre; E A Wu; J W Horner; R A DePinho
Journal:  Nature       Date:  2001-09-06       Impact factor: 49.962

5.  Differential expression of p16(INK4a) in azoxymethane-induced mouse colon tumorigenesis.

Authors:  Q S Wang; A Papanikolaou; P R Nambiar; D W Rosenberg
Journal:  Mol Carcinog       Date:  2000-07       Impact factor: 4.784

6.  Inhibition of colon tumor progression and angiogenesis by the Ink4a/Arf locus.

Authors:  Steven L Gibson; Charlotte Y Dai; Han-Woong Lee; Ronald A DePinho; Michael S Gee; William M F Lee; Emma E Furth; Colleen Brensinger; Greg H Enders
Journal:  Cancer Res       Date:  2003-02-15       Impact factor: 12.701

Review 7.  Tumor suppression by Ink4a-Arf: progress and puzzles.

Authors:  Scott W Lowe; Charles J Sherr
Journal:  Curr Opin Genet Dev       Date:  2003-02       Impact factor: 5.578

8.  Adenovirus-mediated gene transfer of P16INK4/CDKN2 into bax-negative colon cancer cells induces apoptosis and tumor regression in vivo.

Authors:  Ingo Tamm; Axel Schumacher; Leonid Karawajew; Velia Ruppert; Wolfgang Arnold; Andreas K Nüssler; Peter Neuhaus; Bernd Dörken; Gerhard Wolff
Journal:  Cancer Gene Ther       Date:  2002-08       Impact factor: 5.987

9.  Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis.

Authors:  Robert M Bachoo; Elizabeth A Maher; Keith L Ligon; Norman E Sharpless; Suzanne S Chan; Mingjian James You; Yi Tang; Jessica DeFrances; Elizabeth Stover; Ralph Weissleder; David H Rowitch; David N Louis; Ronald A DePinho
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

10.  A novel function for the tumor suppressor p16(INK4a): induction of anoikis via upregulation of the alpha(5)beta(1) fibronectin receptor.

Authors:  T Plath; K Detjen; M Welzel; Z von Marschall; D Murphy; M Schirner; B Wiedenmann; S Rosewicz
Journal:  J Cell Biol       Date:  2000-09-18       Impact factor: 10.539

View more
  10 in total

1.  Kip3-ing kinetochores clustered.

Authors:  Ryoma Ohi
Journal:  Cell Cycle       Date:  2010-07-01       Impact factor: 4.534

2.  INK4a deletion results in improved kidney regeneration and decreased capillary rarefaction after ischemia-reperfusion injury.

Authors:  David H Lee; Jesse M Wolstein; Basu Pudasaini; Matthew Plotkin
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-28

3.  Transgenic expression of VEGF in intestinal epithelium drives mesenchymal cell interactions and epithelial neoplasia.

Authors:  Amelie Boquoi; Rodrigo Jover; Tina Chen; Marieke Pennings; Greg H Enders
Journal:  Gastroenterology       Date:  2008-11-01       Impact factor: 22.682

Review 4.  Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review.

Authors:  Kaori Shima; Katsuhiko Nosho; Yoshifumi Baba; Mami Cantor; Jeffrey A Meyerhardt; Edward L Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Int J Cancer       Date:  2011-03-01       Impact factor: 7.396

5.  Utility of p16 immunohistochemistry for the identification of Lynch syndrome.

Authors:  Artemio Payá; Cristina Alenda; Lucía Pérez-Carbonell; Estefanía Rojas; José-Luis Soto; Carmen Guillén; Adela Castillejo; Victor M Barberá; Alfredo Carrato; Antoni Castells; Xavier Llor; Montserrat Andreu; Jim Koh; Greg H Enders; Susana Benlloch; Rodrigo Jover
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

Review 6.  Wnt-signaling and senescence: A tug of war in early neoplasia?

Authors:  Peter D Adams; Greg H Enders
Journal:  Cancer Biol Ther       Date:  2008-11-07       Impact factor: 4.742

7.  Chemoprevention of mouse intestinal tumorigenesis by the cyclin-dependent kinase inhibitor SNS-032.

Authors:  Amelie Boquoi; Tina Chen; Greg H Enders
Journal:  Cancer Prev Res (Phila)       Date:  2009-09-01

8.  Inducible re-expression of p16 in an orthotopic mouse model of pancreatic cancer inhibits lymphangiogenesis and lymphatic metastasis.

Authors:  P Schulz; A Scholz; A Rexin; P Hauff; M Schirner; B Wiedenmann; K Detjen
Journal:  Br J Cancer       Date:  2008-06-24       Impact factor: 7.640

9.  Reversible cell cycle inhibition and premature aging features imposed by conditional expression of p16Ink4a.

Authors:  Amelie Boquoi; Sanjeevani Arora; Tina Chen; Sam Litwin; James Koh; Greg H Enders
Journal:  Aging Cell       Date:  2014-12-06       Impact factor: 9.304

10.  Disruption of the RP-MDM2-p53 pathway accelerates APC loss-induced colorectal tumorigenesis.

Authors:  S Liu; N R Tackmann; J Yang; Y Zhang
Journal:  Oncogene       Date:  2016-09-12       Impact factor: 9.867

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.